NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: University of Bern
Conditions: Hiv
Countries: Argentina, Brazil, Burkina Faso, Cambodia, Cameroon, Côte d’Ivoire, Kenya, Malawi
This is a prospective observational study enrolling People Living with HIV (PLHIV) who are on a Dolutegravir-based AntiRetroviral Treatment (ART) regimen and experiencing virologic failure. Virologic failure is defined as two consecutive viral load measurements of \>1000 copies/mL of blood. The main aim of the study is to identify the drug-resistance mutations in the viral genome that are associated with this failure. To achieve this goal, patients fulfilling the eligibility criteria will be invited for a single study visit for the collection of blood. The extracted HIV virus will be sequenced through whole genome sequencing methods to identify the drug-resistance mutations. The study is conducted in 15-20 countries within six regions of the IeDEA cohort (International epidemiology Databases to Evaluate AIDS).
Sex: ALL
Age: 10 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Adults aged 18 years or older and adolescents (10-17 years) * On any DTG-based ART regimen * Who develop virologic failure (VF) defined as a VL \>1000 copies/mL (single or confirmed measurement), * and have signed the informed consent. Exclusion Criteria: * No Informed Consent
- Buenos Aires, Argentina
- Rio de Janeiro, Brazil
- Bobo-Dioulasso, Burkina Faso
- Phnom Penh, Cambodia
- Limbe, Cameroon
- Yaoundé, Cameroon
- Abidjan, Côte d’Ivoire
- Abidjan, Côte d’Ivoire
- Eldoret, Kenya
- Lilongwe, Malawi
- Lilongwe, Malawi
- Mexico City, Mexico
- Brazzaville, Republic of the Congo
- Pointe-Noire, Republic of the Congo
- Kigali, Rwanda
- Kisesa, Tanzania
- Bangkok, Thailand
- Bangkok, Thailand
- Masaka, Uganda
- Mbarara, Uganda
- Lusaka, Zambia
- Harare, Zimbabwe